公开(公告)号：US6037175A

公开(公告)日：2000-03-14

申请号：US615039

申请日：1996-03-12

申请人： Don F. Cameron ,  Paul R. Sanberg ,  Cesario V. Borlongan ,  Samuel Saporta

发明人： Don F. Cameron ,  Paul R. Sanberg ,  Cesario V. Borlongan ,  Samuel Saporta

IPC分类号： A01N1/02 ,  A61K35/12 ,  C12N5/071 ,  C12N5/0793

CPC分类号： C12N5/0683 ,  A01N1/0226 ,  C12N5/0619 ,  A61K2035/122 ,  A61K35/12 ,  C12N2502/246

摘要： A method of enhancing the viability of cryopreserved cells is culturing Sertoli cells in media to produce preconditioned media and adding the preconditioned media to the cells to be cryopreserved. The cells are then cryopreserved. Alternatively, a method of enhancing the viability of cryopreserved cells is co-culturing Sertoli cells and cells to be cryopreserved in media and cryopreserving both.

摘要翻译： 提高冷冻保存细胞活力的方法是在培养基中培养Sertoli细胞以产生预处理的培养基，并将预处理的培养基加入待冷冻保存的细胞中。 然后将细胞冷冻保存。 或者，提高冷冻保存细胞的存活力的方法是共培养Sertoli细胞和细胞以在培养基中冷冻保存并冷冻保存两者。

公开(公告)号：US6034079A

公开(公告)日：2000-03-07

申请号：US198882

申请日：1998-11-23

申请人： Paul R. Sanberg ,  Roland D. Shytle ,  Archie A. Silver

发明人： Paul R. Sanberg ,  Roland D. Shytle ,  Archie A. Silver

IPC分类号： A61K31/13 ,  A61K31/445 ,  A61K31/505 ,  A61K31/54

CPC分类号： A61K31/13 ,  A61K31/445 ,  A61K31/505 ,  A61K31/54

摘要： Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.

摘要翻译： 可以通过施用尼古丁拮抗剂，特别是美加明胺来治疗尼古丁反应性神经精神障碍。 麦考胺与精神安定药联合治疗也被公开。 神经精神障碍包括Tourette综合征，精神分裂症，抑郁症，双相情感障碍，震颤，注意缺陷多动障碍，强迫症，hemidystonia，愤怒爆发和迟发性运动障碍。

公开(公告)号：US5942437A

公开(公告)日：1999-08-24

申请号：US799108

申请日：1997-02-11

申请人： Paul R. Sanberg ,  Agneta Othberg ,  Don F. Cameron ,  Samuel Saporta ,  Cesario V. Borlongan

发明人： Paul R. Sanberg ,  Agneta Othberg ,  Don F. Cameron ,  Samuel Saporta ,  Cesario V. Borlongan

IPC分类号： A01N1/02 ,  A61K35/12 ,  C12N5/071 ,  C12N5/0793 ,  A01N63/00

CPC分类号： C12N5/0683 ,  A01N1/0226 ,  C12N5/0619 ,  A61K2035/122 ,  A61K35/12 ,  C12N2502/246

摘要： A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or cryopreservation.

摘要翻译： 在移植（预培养）或低温保存之前通过用Sertoli细胞或sertoli细胞条件培养基（SCM）培养细胞来增加用于移植或冷冻保存的细胞的活力，数量，存活和成熟的方法。

公开(公告)号：US5702700A

公开(公告)日：1997-12-30

申请号：US402389

申请日：1995-03-13

申请人： Paul R. Sanberg ,  Don F. Cameron ,  Cesario V. Borlongan

发明人： Paul R. Sanberg ,  Don F. Cameron ,  Cesario V. Borlongan

IPC分类号： A61K35/48 ,  A01N63/00 ,  A61K35/52 ,  A61K38/22

CPC分类号： A61K35/48

摘要： A method of generating in situ trophic factor production by transplanting Sertoli cells into the central nervous system of a mammal, the cells creating trophic factors in situ.

摘要翻译： 通过将Sertoli细胞移植到哺乳动物的中枢神经系统中产生原位营养因子产生的方法，该细胞原位产生营养因子。

公开(公告)号：US11628190B2

公开(公告)日：2023-04-18

申请号：US16655506

申请日：2019-10-17

申请人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

发明人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

IPC分类号： A61K35/51 ,  A61P25/28 ,  C12N5/0775

摘要： A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

公开(公告)号：US10335434B2

公开(公告)日：2019-07-02

申请号：US14336621

申请日：2014-07-21

申请人： Paul R. Sanberg ,  Alison E. Willing

发明人： Paul R. Sanberg ,  Alison E. Willing

IPC分类号： A61K35/15 ,  A61K35/51 ,  A61K35/12 ,  A61K35/44 ,  C12N5/078 ,  C12N5/0786

摘要： The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

公开(公告)号：US20180325950A1

公开(公告)日：2018-11-15

申请号：US16035936

申请日：2018-07-16

申请人： Jun Tan ,  Paul R. Sanberg

发明人： Jun Tan ,  Paul R. Sanberg

IPC分类号： A61K35/16 ,  A61K35/44 ,  A61K35/12

CPC分类号： A61K35/16 ,  A61K35/44 ,  A61K2035/122

摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid angiopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

公开(公告)号：US10039785B2

公开(公告)日：2018-08-07

申请号：US15195243

申请日：2016-06-28

申请人： Jun Tan ,  Paul R. Sanberg

发明人： Jun Tan ,  Paul R. Sanberg

IPC分类号： A61K35/12 ,  A61K35/16 ,  A61K35/44

摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

公开(公告)号：USD707613S1

公开(公告)日：2014-06-24

申请号：US29468424

申请日：2013-09-30

申请人： Paul R. Sanberg

设计人： Paul R. Sanberg

公开(公告)号：USD707612S1

公开(公告)日：2014-06-24

申请号：US29467860

申请日：2013-09-24

申请人： Paul R. Sanberg

设计人： Paul R. Sanberg